{"id":1843,"date":"2025-09-29T21:02:01","date_gmt":"2025-09-29T21:02:01","guid":{"rendered":"https:\/\/enfoca.com.mx\/?p=1843"},"modified":"2026-10-06T22:49:36","modified_gmt":"2026-10-06T22:49:36","slug":"terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10","status":"publish","type":"post","link":"https:\/\/enfoca.com.mx\/eng\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/","title":{"rendered":"Ocular Gene Therapy: From Luxturna to Optogenetics (MCO-010) and Gene Editing (CRISPR) | Samur A-I #10"},"content":{"rendered":"<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Samur A-I #10 Terapia G\u00e9nica en Oftalmolog\u00eda: El Futuro de la Visi\u00f3n\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/sPJ8BgYSDvY?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Gene Therapy in Ophthalmology: The Future of Vision and Optogenetics<\/h2>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Ophthalmology is on the threshold of a therapeutic revolution driven by <strong>gene therapy<\/strong>. What was once science fiction is now a reality that is redefining the management of devastating diseases. The key for professionals is to understand the leap from one-off treatments to potentially long-lasting solutions.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Luxturna: The Starting Point and Ocular Privilege<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">The drug <strong>Luxturna (RPE65)<\/strong> proved that gene therapy is viable. Its success is largely due to the eye itself. It is an <strong>immune-privileged<\/strong>, anatomically isolated organ. This allows <strong>AAV vectors<\/strong> to be delivered safely and locally.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">The most recent developments focus on how to get the therapy to the right place. <strong>Intravitreal (IVT)<\/strong> injection is now more effective. New vectors, such as the AAV2.7m8 capsid, can cross the inner limiting membrane. This greatly simplifies access to the outer retina, which used to require subretinal surgery.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The New Paradigm: Mutation-Agnostic Therapies<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The most radical change is the arrival of therapies that work without correcting the original mutation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"translation-block\"><strong>Optogenetics (MCO\u2212010):<\/strong> This technology \"rewires\" the retina. It introduces light-sensitive proteins (opsins) into inner retinal cells (such as bipolar cells) that survive the disease. MCO-010, delivered by intravitreal injection, has shown promising results in <strong>retinitis pigmentosa<\/strong>. Patients achieved significant gains in visual acuity.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>Gene editing (CRISPR):<\/strong> This goes beyond gene replacement. CRISPR-Cas9 technology makes it possible to correct <strong>DNA<\/strong> inside the eye. The EDIT\u2212101 trial marked a milestone by reporting functional improvement in Leber congenital amaurosis.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Big Leap: From Rare Diseases to AMD<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">The focus has shifted to far more common diseases. <strong>Wet AMD<\/strong> is the next target. Gene therapies aim to eliminate the burden of repeated anti-VEGF injections. The goal is a <strong>single injection<\/strong> that produces anti-VEGF continuously for years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">The main obstacle to widespread adoption remains <strong>cost<\/strong>. Current pricing models cannot scale to millions of patients. The global ophthalmology community must find manufacturing and financing solutions that allow equitable access.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Where can you find us?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"translation-block\"><strong>YouTube:<\/strong> Subscribe to our channel for full episodes and exclusive content: <a href=\"https:\/\/www.youtube.com\/@SamurEyePodcast\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.youtube.com\/@SamurEyePodcast<\/a><\/li>\n\n\n\n<li class=\"translation-block\"><strong>Instagram:<\/strong> Follow us on Instagram to hear about upcoming topics, guests and highlights: <a href=\"https:\/\/www.instagram.com\/samureyepodcast\/\" target=\"_blank\" rel=\"noreferrer noopener\">@samureyepodcast<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Terapia G\u00e9nica en Oftalmolog\u00eda: El Futuro de la Visi\u00f3n y la Optogen\u00e9tica La oftalmolog\u00eda est\u00e1 en el umbral de una [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[188,196,192,185,194,186,195,190,187,14,174,191,193,111],"class_list":["post-1843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-samur-a-i","tag-amd-gene-therapy","tag-ciencia-y-vision","tag-crispr-cas9","tag-crispr-eye","tag-dmae-terapia-genica","tag-gene-therapy-ophthalmology","tag-luxturna","tag-mco-010","tag-ocular-gene-therapy","tag-oftalmologia","tag-oftalmologo","tag-optogenetica","tag-retinosis-pigmentaria","tag-samureye-podcast"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10<\/title>\n<meta name=\"description\" content=\"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enfoca.com.mx\/eng\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10\" \/>\n<meta property=\"og:description\" content=\"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enfoca.com.mx\/eng\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/\" \/>\n<meta property=\"og:site_name\" content=\"ENFOCA\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T21:02:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-06T22:49:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Riquelme\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Riquelme\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/\"},\"author\":{\"name\":\"Riquelme\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"headline\":\"Terapia G\u00e9nica Ocular: De Luxturna a la Optogen\u00e9tica (MCO-010) y Edici\u00f3n G\u00e9nica (CRISPR) | Samur A-I #10\",\"datePublished\":\"2025-09-29T21:02:01+00:00\",\"dateModified\":\"2026-10-06T22:49:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/SamurAI-10.png\",\"keywords\":[\"AMD Gene Therapy\",\"Ciencia y Visi\u00f3n\",\"CRISPR Cas9\",\"CRISPR Eye\",\"DMAE Terapia G\u00e9nica\",\"Gene Therapy Ophthalmology\",\"Luxturna\",\"MCO-010\",\"Ocular Gene Therapy\",\"Oftalmolog\u00eda\",\"Oftalm\u00f3logo\",\"Optogen\u00e9tica\",\"Retinosis Pigmentaria\",\"SamurEye Podcast\"],\"articleSection\":[\"Samur A-I\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/\",\"name\":\"Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/SamurAI-10.png\",\"datePublished\":\"2025-09-29T21:02:01+00:00\",\"dateModified\":\"2026-10-06T22:49:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"description\":\"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#primaryimage\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/SamurAI-10.png\",\"contentUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/SamurAI-10.png\",\"width\":1920,\"height\":1080,\"caption\":\"Portada de Samur A-I #10: terapia g\u00e9nica ocular\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/enfoca.com.mx\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Terapia G\u00e9nica Ocular: De Luxturna a la Optogen\u00e9tica (MCO-010) y Edici\u00f3n G\u00e9nica (CRISPR) | Samur A-I #10\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/\",\"name\":\"ENFOCA\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/enfoca.com.mx\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\",\"name\":\"Riquelme\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"caption\":\"Riquelme\"},\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/eng\\\/author\\\/drriquelme\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10","description":"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/enfoca.com.mx\/eng\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/","og_locale":"en_US","og_type":"article","og_title":"Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10","og_description":"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.","og_url":"https:\/\/enfoca.com.mx\/eng\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/","og_site_name":"ENFOCA","article_published_time":"2025-09-29T21:02:01+00:00","article_modified_time":"2026-10-06T22:49:36+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png","type":"image\/png"}],"author":"Riquelme","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Riquelme","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#article","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/"},"author":{"name":"Riquelme","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"headline":"Terapia G\u00e9nica Ocular: De Luxturna a la Optogen\u00e9tica (MCO-010) y Edici\u00f3n G\u00e9nica (CRISPR) | Samur A-I #10","datePublished":"2025-09-29T21:02:01+00:00","dateModified":"2026-10-06T22:49:36+00:00","mainEntityOfPage":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/"},"wordCount":482,"image":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png","keywords":["AMD Gene Therapy","Ciencia y Visi\u00f3n","CRISPR Cas9","CRISPR Eye","DMAE Terapia G\u00e9nica","Gene Therapy Ophthalmology","Luxturna","MCO-010","Ocular Gene Therapy","Oftalmolog\u00eda","Oftalm\u00f3logo","Optogen\u00e9tica","Retinosis Pigmentaria","SamurEye Podcast"],"articleSection":["Samur A-I"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/","url":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/","name":"Terapia g\u00e9nica ocular y optogen\u00e9tica | Samur A-I #10","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/#website"},"primaryImageOfPage":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#primaryimage"},"image":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png","datePublished":"2025-09-29T21:02:01+00:00","dateModified":"2026-10-06T22:49:36+00:00","author":{"@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"description":"Luxturna abri\u00f3 la puerta. Ahora exploramos Optogen\u00e9tica (MCO-010) y CRISPR para corregir la DMAE y la Retinosis Pigmentaria. El futuro de la visi\u00f3n.","breadcrumb":{"@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#primaryimage","url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png","contentUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/09\/SamurAI-10.png","width":1920,"height":1080,"caption":"Portada de Samur A-I #10: terapia g\u00e9nica ocular"},{"@type":"BreadcrumbList","@id":"https:\/\/enfoca.com.mx\/terapia-genica-ocular-de-luxturna-a-la-optogenetica-mco-010-y-edicion-genica-crispr-samur-a-i-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/enfoca.com.mx\/"},{"@type":"ListItem","position":2,"name":"Terapia G\u00e9nica Ocular: De Luxturna a la Optogen\u00e9tica (MCO-010) y Edici\u00f3n G\u00e9nica (CRISPR) | Samur A-I #10"}]},{"@type":"WebSite","@id":"https:\/\/enfoca.com.mx\/#website","url":"https:\/\/enfoca.com.mx\/","name":"ENFOCA","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/enfoca.com.mx\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad","name":"Riquelme","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","caption":"Riquelme"},"url":"https:\/\/enfoca.com.mx\/eng\/author\/drriquelme\/"}]}},"_links":{"self":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/comments?post=1843"}],"version-history":[{"count":1,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1843\/revisions"}],"predecessor-version":[{"id":3899,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1843\/revisions\/3899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media\/1844"}],"wp:attachment":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media?parent=1843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/categories?post=1843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/tags?post=1843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}